A Double-blind, Placebo-controlled Multicentre Study of Memantine in Mild to Moderate Vascular Dementia (MMM 500)

1
A Double-blind, Placebo-controlled Multicentre
Study of Memantine in Mild to Moderate Vascular
Dementia (MMM 500)

• Wilcock G., Möbius H.J., and Stöffler A. on
  behalf of the MMM 500 group
• Int Clin Psychopharmacol 2002, 17(6)297-305

2
Study Design
No. of patients N 579 Design Double-blind,
randomized, placebo- controlled, multicenter
study Diagnosis Probable VaD (HIS score ? 4,
DSM-III-R, NINDS-AIREN) Age ? 54 years (mean
77) Severity MMSE 10 - 22 (mean 17.6) Dose
duration 20 mg memantine/day 28 weeks Primary
efficacy Cognition ADAS-cogparameters Global
CGI-C Secondary efficacy MMSE, GBS, NOSGER,
parameters
Wilcock et al., Int Clin Psychopharmacol 2002
3
Significant Benefit of Memantine on Cognition
(ADAS-cog)
ITT, LOCF Mean change from baseline
Improvement
ADAS-cog score difference
Worsening
Week
p lt 0.05 versus placebo
Wilcock et al., Int Clin Psychopharmacol 2002
4
Summary

• Significant cognitive benefit for memantine
  treated patients in mild to moderate vascular
  dementia
• Good safety and tolerability of memantine

Wilcock et al., Int Clin Psychopharmacol 2002